Thrivent Financial for Lutherans Buys New Stake in RxSight, Inc. (NASDAQ:RXST)

Thrivent Financial for Lutherans acquired a new stake in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 229,637 shares of the company's stock, valued at approximately $11,350,000. Thrivent Financial for Lutherans owned about 0.62% of RxSight as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. M&G Plc lifted its position in RxSight by 12.4% during the second quarter. M&G Plc now owns 159,005 shares of the company's stock valued at $9,540,000 after purchasing an additional 17,577 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of RxSight by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company's stock valued at $78,634,000 after acquiring an additional 40,500 shares during the last quarter. Algert Global LLC purchased a new position in RxSight in the second quarter worth about $2,488,000. Caxton Associates LP bought a new stake in RxSight during the first quarter worth approximately $1,208,000. Finally, Bank of New York Mellon Corp raised its position in RxSight by 17.0% during the second quarter. Bank of New York Mellon Corp now owns 119,493 shares of the company's stock valued at $7,190,000 after purchasing an additional 17,368 shares during the period. Hedge funds and other institutional investors own 78.78% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Oppenheimer decreased their price target on RxSight from $72.00 to $65.00 and set an "outperform" rating on the stock in a report on Tuesday, August 6th. Stifel Nicolaus lowered their target price on shares of RxSight from $70.00 to $65.00 and set a "buy" rating for the company in a report on Tuesday, August 6th. Jefferies Financial Group started coverage on shares of RxSight in a report on Tuesday, October 29th. They set a "buy" rating and a $72.00 price target on the stock. Wells Fargo & Company dropped their target price on RxSight from $68.00 to $54.00 and set an "overweight" rating for the company in a research report on Tuesday, August 6th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $66.00 price target on shares of RxSight in a report on Friday, September 13th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $61.63.

RxSight Trading Down 0.5 %

Shares of NASDAQ RXST traded down $0.22 during trading hours on Friday, reaching $44.83. The stock had a trading volume of 540,543 shares, compared to its average volume of 488,710. RxSight, Inc. has a 52-week low of $28.54 and a 52-week high of $66.54. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -55.19 and a beta of 1.19. The business's fifty day moving average price is $49.59 and its two-hundred day moving average price is $52.92.

Insiders Place Their Bets

In related news, Director Jesse Anderson Corley bought 11,111 shares of the company's stock in a transaction on Tuesday, November 12th. The shares were acquired at an average price of $45.37 per share, with a total value of $504,106.07. Following the transaction, the director now owns 468,571 shares of the company's stock, valued at $21,259,066.27. The trade was a 2.43 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Ilya Goldshleger sold 3,100 shares of the business's stock in a transaction on Friday, September 20th. The stock was sold at an average price of $53.19, for a total value of $164,889.00. Following the completion of the transaction, the insider now directly owns 42,246 shares of the company's stock, valued at approximately $2,247,064.74. The trade was a 6.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 52,720 shares of company stock worth $2,603,950. 9.36% of the stock is currently owned by company insiders.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.